Shapiro Aaron, Villarroel Lisa R, George Paul
The Warren Alpert Medical School of Brown University , Providence, RI, USA.
Division of Public Health Preparedness, Arizona Department of Health Services , Phoenix, AZ, USA.
Adv Med Educ Pract. 2019 Aug 2;10:581-583. doi: 10.2147/AMEP.S205946. eCollection 2019.
Physicians who want to prescribe buprenorphine to treat opioid use disorder require a waiver established by the Drug Addiction Treatment Act (DATA) of 2000, often through completion of an eight-hour training course. This is an issue for a number of reasons, including that opioid overdose deaths continue to rise nationally. However, on October 24, 2018, the SUPPORT (Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment) for Patients and Communities Act was signed into law. This bill allows any physician who graduates in good standing from an allopathic or osteopathic medical school in the United States that incorporates necessary material around opioid misuse in their standard curriculum, without need for any additional training, to prescribe buprenorphine. This perspective piece describes why this is an important first step and what more needs to be done within medical education to combat the opioid epidemic.
想要开处方使用丁丙诺啡来治疗阿片类药物使用障碍的医生,需要获得2000年《药物成瘾治疗法案》(DATA)规定的豁免权,通常需要完成一个八小时的培训课程。这一情况存在诸多问题,其中包括全国范围内阿片类药物过量致死人数持续上升。然而,2018年10月24日,《支持患者和社区防治物质使用障碍法案》(SUPPORT)签署成为法律。该法案允许任何从美国正规的全科或骨科医学院毕业、且其标准课程中纳入了有关阿片类药物滥用必要内容的医生,无需任何额外培训即可开处方使用丁丙诺啡。这篇观点文章阐述了为何这是重要的第一步,以及在医学教育中为抗击阿片类药物流行还需要做些什么。